Concentra Group Holdings Parent (CON) investor relations material

Executive summary

• Q2 2026 revenue grew 10.0% year-over-year to $606.0 million, with Adjusted EBITDA up 22.5% to $140.9 million and margin expanding to 23.3% from 20.9% in the prior year quarter.

• Net income attributable to the company rose 46.6% to $65.3 million, with EPS of $0.51 and adjusted EPS of $0.52.

• Leadership transition announced: Matt DiCanio to become CEO and president, Keith Newton to executive chairman, effective November 1, 2026.

• Patient visits and revenue per visit both increased, with visits up 2.6% to 3,610,934 and revenue per visit up 4.6% to $152.67.

• Declared a cash dividend of $0.0625 per share for Q2 2026 and continued share repurchases.

Financial highlights

• Q2 2026 revenue: $606.0 million (up 10.0% year-over-year); Adjusted EBITDA: $140.9 million (23.3% margin); net income attributable to the company: $65.3 million.

• Free cash flow for Q2 2026: $121.0 million, nearly doubling year-over-year; operating cash flow: $135.2 million.

• Cash balance at period end: $158.0 million; net leverage ratio: 2.99x.

• Capital expenditures in Q2 2026: $15.7 million, down 37.9% year-over-year.

• Net debt at quarter end: $1.57 billion; $430 million available under revolving credit facility.

Outlook and guidance

• FY 2026 guidance raised: revenue $2.325–$2.375 billion, Adjusted EBITDA $485–$495 million, free cash flow $220–$240 million, capital expenditures $70–$80 million.

• Net leverage ratio expected to remain below 3.0x for the year.

• Management expects continued growth through organic expansion, strategic acquisitions, and strong visit and rate growth.

• Sufficient liquidity and borrowing capacity to support operations and growth initiatives.

• Some conservatism in outlook due to market variability and seasonality.